|
US5534263A
(en)
*
|
1995-02-24 |
1996-07-09 |
Alza Corporation |
Active agent dosage form comprising a matrix and at least two insoluble bands
|
|
CA2173818A1
(fr)
*
|
1996-04-10 |
1997-10-11 |
Francois Chouinard |
Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
|
|
US5804165A
(en)
*
|
1996-07-24 |
1998-09-08 |
Arnold; Michael J. |
Antiplaque oral composition
|
|
DE19640062B4
(de)
*
|
1996-09-28 |
2006-04-27 |
Lts Lohmann Therapie-Systeme Ag |
Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
|
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
IT1294760B1
(it)
*
|
1997-09-03 |
1999-04-12 |
Jagotec Ag |
Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
|
|
IN186245B
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
GB9724186D0
(en)
|
1997-11-14 |
1998-01-14 |
British Tech Group |
Low temperature coatings
|
|
PE20000066A1
(es)
*
|
1997-12-22 |
2000-02-09 |
Schering Corp |
Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
|
|
KR20010052557A
(ko)
*
|
1998-06-05 |
2001-06-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
산화마그네슘을 사용한, ａｃｅ 억제제 함유 조성물의안정화
|
|
IL141339A0
(en)
*
|
1998-09-25 |
2002-03-10 |
Delsys Pharmaceutical Corp |
Liquid pharmaceutical for oral delivery
|
|
US6416786B1
(en)
|
1998-12-11 |
2002-07-09 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
|
FR2797185B1
(fr)
*
|
1999-08-06 |
2001-10-26 |
Galenix Dev |
Composition pharmaceutique flottante comprenant une phase active et une phase non active
|
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
|
JP4565456B2
(ja)
*
|
1999-11-02 |
2010-10-20 |
塩野義製薬株式会社 |
着色顆粒の色素定着法
|
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
|
AR030557A1
(es)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
|
US6881420B2
(en)
*
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
|
WO2002000213A1
(en)
*
|
2000-06-23 |
2002-01-03 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
|
WO2003097018A1
(en)
*
|
2002-02-04 |
2003-11-27 |
Ranbaxy Laboratories Limited |
Hydrodynamically balancing oral drug delivery system with biphasic release
|
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
AU2141202A
(en)
*
|
2000-12-05 |
2002-06-18 |
Alexander Macgregor |
Hydrostatic delivery system for controlled delivery of agent
|
|
KR100685945B1
(ko)
|
2000-12-29 |
2007-02-23 |
엘지.필립스 엘시디 주식회사 |
액정표시장치 및 그 제조방법
|
|
US8268333B2
(en)
*
|
2001-04-24 |
2012-09-18 |
Lintec Corporation |
Orally administered agent and an orally administered agent/supporting substrate complex
|
|
DE10120092B4
(de)
*
|
2001-04-25 |
2008-03-20 |
Lts Lohmann Therapie-Systeme Ag |
Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
|
|
IL159813A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
|
|
IL159812A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
|
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
CA2409552A1
(en)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US6645526B2
(en)
*
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
|
US20030099699A1
(en)
*
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
|
WO2003042136A2
(en)
*
|
2001-11-13 |
2003-05-22 |
Teva Pharmaceutical Industries, Ltd. |
Process for the production of l-dopa ethyl ester
|
|
AU2002340470A1
(en)
|
2001-11-13 |
2003-05-26 |
Teva Pharmaceutical Industries, Ltd. |
L-dopa ethyl ester salts and uses thereof
|
|
ATE290387T1
(de)
*
|
2001-12-21 |
2005-03-15 |
Biopartners Gmbh |
Ribavirin-granulat zur herstellung von filmtabletten
|
|
KR20030056474A
(ko)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
카르비도파/레보도파 서방정의 조성물과 그의 제조방법
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US7008979B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Hydromer, Inc. |
Coating composition for multiple hydrophilic applications
|
|
US20060013875A1
(en)
*
|
2002-05-29 |
2006-01-19 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
|
PT1551372T
(pt)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
|
WO2004041255A1
(en)
*
|
2002-10-31 |
2004-05-21 |
Alza Corporation |
Dosage form providing ascending release of liquid formulation
|
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
|
CN1917876A
(zh)
|
2003-12-16 |
2007-02-21 |
Cns生物有限公司 |
方法和组合物
|
|
US20070196396A1
(en)
*
|
2004-02-11 |
2007-08-23 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
WO2005084703A1
(ja)
*
|
2004-03-09 |
2005-09-15 |
Nrl Pharma, Inc. |
徐放性の口腔用組成物
|
|
FR2874325B1
(fr)
*
|
2004-08-19 |
2006-10-20 |
Sanofi Synthelabo |
Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
|
|
JP5046946B2
(ja)
*
|
2004-10-15 |
2012-10-10 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
低乱用性薬学的製剤
|
|
EP1830791B1
(en)
*
|
2004-11-19 |
2014-09-10 |
GlaxoSmithKline LLC |
Pharmaceutical product
|
|
AU2005320547B2
(en)
*
|
2004-12-27 |
2009-02-05 |
Eisai R & D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
|
US20070148238A1
(en)
*
|
2005-06-23 |
2007-06-28 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
|
EA200800162A1
(ru)
*
|
2005-06-29 |
2008-06-30 |
Панацея Биотек Лтд. |
Новые фармацевтические композиции с замедленным высвобождением и способы их получения
|
|
ES2620293T3
(es)
*
|
2005-09-09 |
2017-06-28 |
Paladin Labs Inc. |
Composición de liberación sostenida de fármacos
|
|
EA014739B1
(ru)
*
|
2005-09-09 |
2011-02-28 |
Лабофарм Инк. |
Композиция тразодона для введения один раз в день
|
|
NL2000281C2
(nl)
|
2005-11-02 |
2007-08-07 |
Pfizer Prod Inc |
Vaste farmaceutische samenstellingen die pregabaline bevatten.
|
|
EP1945189A4
(en)
|
2005-11-03 |
2012-08-15 |
Sun Pharmaceutical Ind Ltd |
CONTROLLED RELEASE COATED TABLETS CHARACTERIZED BY PROLONGED GASTRIC RETENTION
|
|
EP1945188A2
(en)
*
|
2005-11-07 |
2008-07-23 |
Teva Pharmaceutical Industries Ltd. |
Levodopa compositions
|
|
US7674396B2
(en)
*
|
2005-11-08 |
2010-03-09 |
Plensat Llc |
Method and system for treatment of eating disorders
|
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
|
KR100752417B1
(ko)
*
|
2006-02-14 |
2007-08-28 |
대원제약주식회사 |
안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
|
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
|
EP2021005A4
(en)
*
|
2006-05-03 |
2009-11-25 |
Cnsbio Pty Ltd |
METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
|
|
AU2007266574A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
|
CN101677963B
(zh)
|
2006-06-19 |
2012-05-30 |
奥尔制药公司 |
药物组合物
|
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
|
JP2010501607A
(ja)
*
|
2006-08-30 |
2010-01-21 |
ヤゴテック アーゲー |
ニソルジピンを含有する徐放性の固体状経口投与用配合剤
|
|
WO2008041553A1
(fr)
*
|
2006-09-26 |
2008-04-10 |
Astellas Pharma Inc. |
Préparation à libération entretenue de tacrolimus
|
|
WO2008039193A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
|
BRPI0622039B1
(pt)
*
|
2006-09-26 |
2020-11-10 |
Plensat, Llc |
dispositivos gástricos ingeríveis de qualidade alimentícia
|
|
EP1935411A1
(en)
|
2006-12-15 |
2008-06-25 |
Campina Nederland Holding B.V. |
Slow release excipient and its use
|
|
EP2063867A2
(en)
*
|
2006-12-22 |
2009-06-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
|
JPWO2008084698A1
(ja)
|
2006-12-28 |
2010-04-30 |
アステラス製薬株式会社 |
タクロリムス徐放性医薬組成物
|
|
AT505225A1
(de)
|
2007-04-26 |
2008-11-15 |
Sanochemia Pharmazeutika Ag |
0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
RU2011101459A
(ru)
*
|
2008-06-16 |
2012-07-27 |
Аппиан Лабс, Ллк (Us) |
Композиция и способ получения систем высвобождения для постоянного (нулевого порядка) высвобождения активных средств
|
|
JP2012500221A
(ja)
*
|
2008-08-15 |
2012-01-05 |
ディポメド，インコーポレイティド |
Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
|
|
EP2349221A4
(en)
*
|
2008-10-08 |
2013-03-27 |
Bioplus Life Sciences Pvt Ltd |
DRUG RELEASE SYSTEM WITH DELAYED RELEASE
|
|
US20100112054A1
(en)
*
|
2008-10-23 |
2010-05-06 |
Appian Labs, Llc |
Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
|
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
|
EP2210585A1
(en)
|
2009-01-16 |
2010-07-28 |
Exelgyn |
SPRM pharmaceutical compositions methods of treatment using them
|
|
US20100249423A1
(en)
*
|
2009-03-09 |
2010-09-30 |
Sanochemia Pharmazeutika Ag |
Tolperisone controlled release tablet
|
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
US10485770B2
(en)
|
2009-12-21 |
2019-11-26 |
Aptapharma, Inc. |
Functionally-coated multilayer tablets
|
|
TR201802207T4
(tr)
|
2010-03-29 |
2018-03-21 |
Astellas Pharma Inc |
Kontrollü Salımlı Farmasötik Bileşim.
|
|
JP5459670B2
(ja)
*
|
2010-05-07 |
2014-04-02 |
塩野義製薬株式会社 |
着色顆粒の色素定着化剤
|
|
US20130143867A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
AU2013213317B2
(en)
|
2012-01-23 |
2016-06-30 |
Sun Pharmaceutical Industries Limited |
In-situ multilayered tablet technology
|
|
EP3003297A4
(en)
|
2013-06-05 |
2017-04-19 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
|
JP6506271B2
(ja)
|
2013-10-07 |
2019-04-24 |
インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． |
レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
|
|
MX2016015891A
(es)
|
2014-06-02 |
2017-07-11 |
Teva Pharma |
Forma de dosis gastrorretentiva expansible.
|
|
GB201506755D0
(en)
|
2015-04-21 |
2015-06-03 |
Reckitt Benckiser Llc |
Novel pharmaceutical formulation
|
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
|
US10363288B2
(en)
|
2015-01-14 |
2019-07-30 |
National Jewish Health |
Insulin mimotopes and methods of using the same
|
|
WO2016128973A1
(en)
*
|
2015-02-09 |
2016-08-18 |
Entera Bio Ltd. |
Treatment of osteoporosis
|
|
WO2016174664A1
(en)
|
2015-04-29 |
2016-11-03 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
|
EP3364955B1
(en)
|
2015-10-09 |
2022-04-20 |
RB Health (US) LLC |
Pharmaceutical formulation
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9820957B2
(en)
|
2016-03-24 |
2017-11-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of treating autoimmunity
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
CN116831977A
(zh)
|
2016-08-17 |
2023-10-03 |
安提拉生物有限公司 |
用于口服的活性剂的制剂
|
|
ES2966736T3
(es)
|
2016-12-02 |
2024-04-24 |
Clexio Biosciences Ltd |
Sistema de residencia gástrica
|
|
KR102039345B1
(ko)
*
|
2017-02-01 |
2019-11-01 |
지엘팜텍주식회사 |
프레가발린 함유 고팽윤성 서방성 삼중정제
|
|
JP7433226B2
(ja)
|
2017-12-01 |
2024-02-19 |
ウルトラジェニクス ファーマシューティカル インク． |
クレアチンプロドラッグ、組成物及びその使用方法
|
|
US11547839B2
(en)
|
2017-12-04 |
2023-01-10 |
Clexio Biosciences Ltd. |
Long acting gastric residence system
|
|
WO2019126215A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
|
US11337919B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
|
|
US11052060B2
(en)
|
2018-02-12 |
2021-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and methods for treating autoimmunity
|
|
US11013707B2
(en)
|
2018-03-23 |
2021-05-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Administration of oral methyldopa
|
|
JP7550393B2
(ja)
*
|
2018-05-15 |
2024-09-13 |
ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド |
低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
|
|
CN110214860A
(zh)
*
|
2019-07-10 |
2019-09-10 |
聂刘明 |
一种宠物饲料及其制备工艺
|
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
US12194150B2
(en)
|
2020-12-22 |
2025-01-14 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
CA3226223A1
(en)
*
|
2021-07-30 |
2023-02-02 |
Jacob Pade Ramsoe Jacobsen |
5-hydroxytryptophan gastroretentive dosage forms
|
|
US11779567B2
(en)
|
2021-10-14 |
2023-10-10 |
Evecxia Therapeutics, Inc. |
Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
|
WO2023214018A1
(en)
|
2022-05-06 |
2023-11-09 |
Galenix Innovations |
Gastro-retentive swellable sustained release composition
|